Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AdCh3NSmut1 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group 1 | EXPERIMENTAL | Interventions: AdCh3NSmut1, MVA-NSmut. Administration schedule: 1 dose AdCh3NSmut1 2.5 x 10\^10 vp at week 0 and 1 dose MVA-NSmut 2 x 10\^8 pfu at week 8. Subjects: 20 HIV seropositive individuals |
| Name | Type | Description |
|---|---|---|
| AdCh3NSmut1 | BIOLOGICAL | Genetic vaccine against Hepatitis C virus infection |
| MVA-NSmut | BIOLOGICAL | Genetic vaccine against Hepatitis C virus infection |
Inclusion Criteria: * HIV-1 seropositive adults must satisfy all the following inclusion criteria to be eligible for the study: * Aged 18 to 60 years (inclusive) * Resident in or near the trial sites for the duration of the vaccination study for the participant * Able and willing (in the Inv...
AdCh3NSmut1 is an investigational vaccine candidate developed by GSK plc for Hepatitis C Infection. It has been studied in a Phase 1 clinical trial in HIV seropositive individuals. The candidate is designed to assess safety in this population. It is not approved for any indication and remains in clinical development.
AdCh3NSmut1 is being developed for the prevention or treatment of Hepatitis C Infection. It has been evaluated in a Phase 1 trial involving HIV seropositive individuals. The study assessed the safety of Hepatitis C vaccine candidates. AdCh3NSmut1 is investigational and has not been approved for use.
AdCh3NSmut1 is developed by GSK plc, which trades under the ticker GSK. GSK is the sponsor of the clinical program for this Hepatitis C vaccine candidate. The company conducted a Phase 1 trial in HIV seropositive individuals to assess safety.
AdCh3NSmut1 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are ongoing. The trial enrolled 20 participants. AdCh3NSmut1 is investigational and has not received regulatory approval for any indication.
AdCh3NSmut1 has been studied in one completed Phase 1 trial, NCT02568332, titled "A Study to Assess the Safety of Hep C Vaccine Candidates in HIV Seropositive Individuals." The trial enrolled 20 participants across Ireland and Switzerland. It was an uncontrolled study without randomization or blinding.